secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-256958
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Therapeutic reports positive Phase 1b Part B data for TX45 in PH-HFrEF
-------------------------------------------------------------------------------

- Single dose of TX45 improved left heart function and pulmonary hemodynamics: PCWP -29.2%, CO +17.3%, mPAP -19.3%, TPR -29.2% mean change.
- In CpcPH patients (PVR>3 WU), PVR reduced -19.7%; PVR >2 WU group showed -10.3% mean change.
- Echocardiographic improvements at day 29: LVEF +19.4%, RVFAC +20.3%, TAPSE/SPAP +36.3% mean change.
- TX45 well tolerated with no serious or severe adverse events, no clinically significant BP changes or immune reactions.
- APEX Phase 2 trial in PH-HFpEF ongoing; topline results expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525256958/0001193125-25-256958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525256958/d30823d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-256958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer